Addiction and OUD treatment knowledge

The manuals converge on the need for a solid grasp of addiction treatment context, especially how opioid use disorder is understood and managed within existing care. Across the opioid-focused extracts, there is shared emphasis on core OUD symptoms, craving, relapse risk, the role of medication-assisted or opioid agonist treatment, and the fact that participants may continue usual medical care while an investigational intervention is being studied. They also agree that adjunctive approaches are being tested because standard treatment does not fit every case equally well. In the buprenorphine-linked MORE+KAP extract, the rationale is framed as an investigational augmentation to ongoing treatment. In the ibogaine extract, the focus is on severe, treatment-refractory OUD, including people who have not responded to or have declined methadone or buprenorphine. The tobacco psilocybin extract similarly treats hallucinogen-assisted therapy as investigational and as a potentially efficacious adjunct, with pilot findings described as feasible but not definitive. The main differences are in the target population and the treatment logic. The OUD manuals centre on opioid agonist therapy, buprenorphine, methadone, and refractory opioid use disorder, while the tobacco manual is about smoking cessation and hallucinogen-facilitated treatment more broadly.